Please note: The information displayed on this page might be outdated.
Dynacure: Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders. The company maintains its headquarters in Strasbourg, France. Dynacure’s investors are Andera Partners, Bpifrance, IdInvest, Ionis Pharmaceuticals, Kurma Partners and Pontifax.
Phase l or ll
Central Nervous System, Pain, Rare Disease
Illkirch-Graffenstaden, Alsace F-67400
Company Participants at Solebury Trout Corporate Access Calls - May 11&12
- David Garrett, CFO
- Stéphane van Rooijen, MD MBA, CEO